AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NYSEAMERICAN:VNRXVolitionRX Stock Price, Forecast & News

$3.50
+0.25 (+7.69 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.35
Now: $3.50
$3.52
50-Day Range N/A
52-Week Range
$2.22
Now: $3.50
$6.84
Volume243,273 shs
Average Volume252,905 shs
Market Capitalization$144.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Read More
VolitionRX logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$144.22 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of VolitionRX?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VolitionRX.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for VolitionRX.

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) announced its quarterly earnings data on Thursday, May, 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.04. The medical research company earned $0.54 million during the quarter. View VolitionRX's earnings history.

What price target have analysts set for VNRX?

3 brokers have issued twelve-month target prices for VolitionRX's shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate VolitionRX's share price to reach $8.33 in the next year. This suggests a possible upside of 138.1% from the stock's current price. View analysts' price targets for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

News stories about VNRX stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. VolitionRX earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about VolitionRX.

Are investors shorting VolitionRX?

VolitionRX saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 544,700 shares, an increase of 26.3% from the June 15th total of 431,200 shares. Based on an average daily trading volume, of 299,600 shares, the short-interest ratio is presently 1.8 days. Approximately 2.0% of the shares of the stock are sold short. View VolitionRX's Current Options Chain.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRX investors own include Chesapeake Energy (CHK), Bausch Health Companies (BHC), Verastem (VSTM), Bausch Health Companies (BHC), Ring Energy (REI), Ring Energy (REI), Crispr Therapeutics (CRSP), Exelixis (EXEL), Gilead Sciences (GILD) and ContraFect (CFRX).

Who are VolitionRX's key executives?

VolitionRX's management team includes the following people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.50.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $144.22 million. VolitionRX employs 44 workers across the globe.

What is VolitionRX's official website?

The official website for VolitionRX is www.volitionrx.com.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.